Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of a single oral dose of vanoxerine for the conversion of subjects with recent onset atrial fibrillation or flutter to normal sinus rhythm: RESTORE SR

Heart Rhythm

Volumn 13, Issue 9, 2016, Pages 1777-1783

  Piccini, Jonathan P ^a   Pritchett, Edward L C ^a   Davison, Beth A ^b   Cotter, Gad ^b   Wiener, Laura E ^c   Koch, Gary ^c   Feld, Gregory ^d   Waldo, Albert ^e   van Gelder, Isabelle C ^f   Camm, A John ^g   Kowey, Peter R ^h   Iwashita, Julie ⁱ   Dittrich, Howard C ⁱ  

^a DUKE UNIVERSITY   (United States)

^b Momentum Research Inc   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e CASE WESTERN RESERVE UNIVERSITY   (United States)

^f UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^g ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^h LANKENAU INSTITUTE FOR MEDICAL RESEARCH   (United States)

ⁱ Laguna Pharmaceuticals   (United States)

Author keywords

Antiarrhythmic; Atrial fibrillation; Cardioversion; Clinical trial; Vanoxerine

Indexed keywords

AMIODARONE; PLACEBO; TROPONIN; VANOXERINE; ANTIARRHYTHMIC AGENT; PIPERAZINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ALL CAUSE MORTALITY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVERSION; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FLUTTER; HEART DISEASE; HEART PROARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE BIGEMINY; HEART VENTRICLE FIBRILLATION; HUMAN; LENGTH OF STAY; MALE; PRIORITY JOURNAL; QTC INTERVAL; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; TACHYCARDIA; TORSADE DES POINTES; TREATMENT OUTCOME; CHEMICALLY INDUCED; CLINICAL TRIAL; DRUG EFFECTS; HEART RATE; HEART VENTRICLE TACHYCARDIA; MIDDLE AGED; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PROSPECTIVE STUDY;

ADMINISTRATION, ORAL; AGED; ANTI-ARRHYTHMIA AGENTS; ATRIAL FIBRILLATION; ATRIAL FLUTTER; DOUBLE-BLIND METHOD; FEMALE; HEART RATE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; TACHYCARDIA, VENTRICULAR; TREATMENT OUTCOME;

EID: 84971657223     PISSN: 15475271     EISSN: 15563871     Source Type: Journal    
DOI: 10.1016/j.hrthm.2016.04.012     Document Type: Article

References (19)

1. Naccarelli, G.V., Varker, H., Lin, J., Schulman, K.L., Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 104 (2009), 1534–1539.
2. January, C.T., Wann, L.S., Alpert, J.S., et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130 (2014), 2071–2104.
3. Stambler, B.S., Wood, M.A., Ellenbogen, K.A., Perry, K.T., Wakefield, L.K., VanderLugt, J.T., Ibutilide Repeat Dose Study Investigators. Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 94 (1996), 1613–1621.
4. Lacerda, A.E., Kuryshev, Y.A., Yan, G.X., Waldo, A.L., Brown, A.M., Vanoxerine: cellular mechanism of a new antiarrhythmic. J Cardiovasc Electrophysiol 21 (2010), 301–310.
5. Dittrich, H.C., Feld, G.K., Bahnson, T.D., Camm, A.J., Golitsyn, S., Katz, A., Koontz, J.I., Kowey, P.R., Waldo, A.L., Brown, A.M., COR-ART: a multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. Heart Rhythm 12 (2015), 1105–1112.
6. Camm, A.J., Lip, G.Y., De Caterina, R., et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33 (2012), 2719–2747.
7. Connolly, S.J., Schnell, D.J., Page, R.L., Wilkinson, W.E., Marcello, S.R., Pritchett, E.L., Symptoms at the time of arrhythmia recurrence in patients receiving azimilide for control of atrial fibrillation or flutter: results from randomized trials. Am Heart J 146 (2003), 489–493.
8. Agresti, A., Caffo, B., Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 54 (2000), 280–288.
9. Lan, K.K., Wittes, J., The B-value: a tool for monitoring data. Biometrics 44 (1988), 579–585.
10. Bertran, G.C., Biagetti, M.O., Valverde, E.R., Quinteiro, R.A., Effects of amiodarone and desethylamiodarone on the inward rectifying potassium current (IK1) in rabbit ventricular myocytes. J Cardiovasc Pharmacol 31 (1998), 914–920.
11. Kodama, I., Kamiya, K., Toyama, J., Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 84 (1999), 20R–28R.
12. Kramer, J., Obejero-Paz, C.A., Myatt, G., Kuryshev, Y.A., Bruening-Wright, A., Verducci, J.S., Brown, A.M., MICE models: superior to the HERG model in predicting torsade de pointes. Sci Rep, 3, 2013, 2100.
13. Said, T.H., Wilson, L.D., Jeyaraj, D., Fossa, A.A., Rosenbaum, D.S., Transmural dispersion of repolarization as a preclinical marker of drug-induced proarrhythmia. J Cardiovasc Pharmacol 60 (2012), 165–171.
14. Tikosyn [package insert]. 2014, Pfizer, Inc, New York, NY.
15. Obejero-Paz, C.A., Bruening-Wright, A., Kramer, J., Hawryluk, P., Tatalovic, M., Dittrich, H.C., Brown, A.M., Quantitative profiling of the effects of vanoxerine on human cardiac ion channels and its application to cardiac risk. Sci Rep, 5, 2015, 17623.
16. Hohnloser, S.H., Dorian, P., Straub, M., Beckmann, K., Kowey, P., Safety and efficacy of intravenously administered tedisamil for rapid conversion of recent-onset atrial fibrillation or atrial flutter. J Am Coll Cardiol 44 (2004), 99–104.
17. Camm, A.J., The vernakalant story: how did it come to approval in Europe and what is the delay in the U.S.A?. Curr Cardiol Rev 10 (2014), 309–314.
18. Mazur, A., Anderson, M.E., Bonney, S., Roden, D.M., Pause-dependent polymorphic ventricular tachycardia during long-term treatment with dofetilide: a placebo-controlled, implantable cardioverter-defibrillator-based evaluation. J Am Coll Cardiol 37 (2001), 1100–1105.
19. Abraham, J.M., Saliba, W.I., Vekstein, C., et al. Safety of oral dofetilide for rhythm control of atrial fibrillation and atrial flutter. Circ Arrhythm Electrophysiol 8 (2015), 772–776.